Search PubMed⌕ Search

Biomedical subjects

T Kotake

Publications and source records attributed to T Kotake.

At least 235 records · Page 13Linked to original sources
PubMed1986

[Recent progress and problems in bladder-sparing operations in bladder tumors].

Retrospective analysis of the bladder tumor patients was performed to reveal the clinical results of partial cystectomy or transurethral resection (TUR). The observed 3-, 5-, 10-year survival rates after 143 partial cystectomies indicated for the first tumors were 66.2%, 57.1% and 41.5% respectively. To obtain satisfactory results, however, the operation should be indicated for pT2 or G0-G1. Some of the G2 tumors could also be the candidates for this procedure, but the stage of the disease must be below T2. At present, all these tumors could be well controlled by TUR, and this statement was confirmed by the study of clinical results obtained by TUR. The analysis also revealed a poor outcome in 6% of the low grade or low stage tumors and it increased to 25% in high grade and pT2. The complete cure of the high stage or high grade tumor is still difficult, but to improve the survival rate, radical surgery should be employed more positively instead of partial cystectomy. The reasons for this conclusion are also discussed.

Female↗
PubMed1985

Comparison of subcellular proteins of normal prostate, benign prostatic hypertrophy, and prostatic cancer: presence of BPH-associated nonhistone proteins.

Proteins in the cytosol, postnuclear particulate, and nuclear fractions from seven specimens of normal prostate from bladder cancer patients, 14 specimens of benign hypertrophic prostate (BPH), and three specimens of cancerous prostate were analyzed and compared by SDS-polyacrylamide slab gel electrophoresis. Abundant protein species in the cytosol fractions were 60K (species having a molecular weight of about 60,000) and 42K; their relative contents were about 35% for 60K and about 12% for 42K. In the postnuclear particulate fraction, 42K was the most abundant (about 10% of the total). The contents of these major protein species were similar in specimens of normal and diseased prostates. In addition, there are marked similarities in the electrophoretic patterns for all the protein (24-29 species) in the cytosol and postnuclear particulate fractions of the human prostate, except for four minor species in the cytosol fraction. Of the nuclear proteins, the content of core histones (H2A, H2B, H3, and H4) was fundamentally similar among all the specimens, whereas the content of H1 histone was different from one specimen to another. The most remarkable and significant difference was that the 42K-NHP (nonhistone protein having a molecular weight of about 42,000), 55K-NHP, and 190K-NHP concentrations were significantly higher in BPH than in normal and cancerous prostates.

Chromosomal Proteins, Non-Histone↗
PubMed1985

Human renal cell carcinoma: establishment and characterization of a new cell line (OS-RC-2).

A cell line, designated as OS-RC-2, has been established from a renal cell carcinoma in a 52-yr-old Japanese male patient and maintained for 23 mo. through 60 in vitro passages. The OS-RC-2 formed monolayers of polygonal epithelial cells and lacked contact inhibition. Doubling time of cells was about 60 h at the 30th passage. Electron microscopic findings indicated numerous long microvilli on the cell surface and many glycogen granules in the cytoplasm of this cell line, which are characteristic structures of renal cell carcinoma. Chromosomal analysis revealed that a small portion of this cell line had a hypodiploid modal number of 40 and a large portion had a hypotetraploid modal number of 75. The characteristics of the karyotype were one detected marker chromosome and the translocation between the Chromosomes 2 and 13. Cell line OS-RC-2 was serially transplantable into nude mice, and histopathological findings of heterotransplanted tumor showed a close similarity to those of the original tumor. Histocompatibility antigens of OS-RC-2 were HLA-A9, Bw52, which were identical to those of the peripheral blood lymphocytes of the patient.

Adenocarcinoma↗
PubMed1985

[Present status of the multidisciplinary treatment of advanced testicular tumors].

Present status of multidisciplinary treatment for advanced testicular tumors was reviewed. Recently dramatic changes have occurred in the management of the disease, resulting substantial improvement in ultimate survival. Many developments in chemotherapy, particularly the introduction of cis-platinum, have been largely responsible for the dramatic change in treatment and prognosis. Therapy depends a large extent upon the histological type and stage of tumors. Surgical excision of primary tumors followed by combination chemotherapy is primary mode of treatment in advanced testicular tumors. Standard chemotherapy involves either cis-platinum, vinblastine, and bleomycin (PVB therapy), or the above 3 drugs combined with actinomycin D and cyclophosphamide (VAB-6 therapy). These therapies have produced complete remission rates of 50%-70% and improved the frequency of long-term survival. Furthermore, post-chemotherapy residual tumors should be treated by aggressive combined therapy with mainly surgery, radiation, and added chemotherapy. The treatment goal for this disease is the achievement of disease free status, namely complete cure.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1985

[The clinical evaluation of hochuekkito for symptoms of malignant neoplasm patients].

Hochuekkito was administered in 2.5 g doses three times a day to 162 patients who complained of anorexia or lassitude because of genitourinary cancer. The efficacy rate was 63.0%. The rate of effectiveness on anorexia was 48.4% and that on lassitude was 36.6%. Side effects were observed in 12 patients (7.4%), but most of them were mild gastrointestinal disorders. No severe adverse effects were noted.

Adult↗
PubMed1985

[Nonsurgical treatment of renovascular hypertension by percutaneous transluminal angioplasty].

A case of renovascular hypertension treated with percutaneous transluminal angioplasty is reported. Our patient was a 22-year-old housewife with 90 per cent stenosis of the right renal artery due to fibromuscular dysplasia. The renal artery was dilatated by percutaneous transluminal angioplasty with a Grützig balloon catheter to 25 per cent stenosis. Five hours after the procedure, blood pressure decreased from 180/114 mmHg to 130/95 mmHg; one day after, plasma renin activity fell from 4.7 ng/ml/hr to 1.7 ng/ml/hr. The patient was rehospitalized six months after percutaneous transluminal angioplasty to examine restenosis of the dilatated renal artery. Although her blood pressure remained normotensive and plasma renin activity was normal, replasty was performed since selective renal arteriography revealed 50 per cent stenosis.

Adult↗
PubMed1985

Multiple primary cancers (MPC) associated with bladder cancer: an analysis of the clinical and autopsy cases in Japan.

Three hundred seventy-two clinical cases of multiple primary cancers (MPCs) involving bladder cancer (reported in the Japanese literature and including 36 of our own cases) and 376 autopsy cases (collected from the tables of the Annuals of Pathological Autopsy Cases in Japan from 1974 to 1981), were analyzed. Of the clinical cases studied, 299 patients were males and 73 females, and their average age was 65.7 years. In the 342 cases having only two primary cancers (PC), the two most common cancers associated with bladder cancer were cancer of the stomach (27.4%) and of the prostate (15.3%) in the males, and cancer of the cervix (27.9%) and of the stomach (16.2%) in the females. In the 119 cases in which the interval was known, the two PC were synchronous in 58 cases and metachronous in 61. In most cases of bladder cancer associated with other urological cancers (85.2%) the two were synchronous. In the females with metachronous cancers, bladder cancer frequently occurred as the second cancer after treatment of cervical or breast cancer. In autopsy cases, the ratio of MPC cases to the total number of cancer cases was 5.2%, and the ratios of MPC cases including bladder cancer to the total number of MPC cases and bladder cancer cases were 5.7% and 15.9%, respectively. The results of a study on organ association between cancer of the urinary bladder and of other organs were almost the same as those in the clinical study except for a lower frequency in other urogenital organs. In an epidemiological analysis of our own cases, the risk of MPC associated with bladder cancer was found to be highest in the stomach, the prostate, the larynx, and the liver. A significant value for the relative risk of a second cancer in another organ following bladder cancer was observed only for the prostate.

Adult↗
PubMed1985

[VM-26 salvage therapy for refractory or recurrent germinal testicular cancers].

Four patients with refractory or recurrent germinal testicular cancers were treated with the combination of VM-26 and cis-platinum, and two of them also in combination with radiation therapy. Two complete responses and two partial responses were observed. One partial response was rendered no evidence of disease by sequential radiation therapy. Three of the patients remained to have no evidence of disease from 16, 21 and 22 months. Toxicity was tolerable. VM-26 is an active drug in germinal testicular cancers and plays an important role in salvage therapy, for refractory or recurrent cases.

Adult↗
PubMed1984

Hormone receptor in renal cell carcinoma and correlation with clinical response to endocrine therapy.

Analyses of hormone receptors in cytosols from 41 renal cell carcinoma specimens were performed by the dextran-coated charcoal technique, using estradiol, synthetic progestin R5020 and synthetic androgen R1881. Binding data were calculated according to the method of Scatchard. Of 41 renal cell carcinomas estradiol receptor was detected in 11, R5020 receptor in 11 and R1881 receptor in 13. No significant correlation between histopathological findings and hormone receptors was observed. Patients were classified into those positive and negative for receptors. The clinical response of endocrine therapy for 17 with advanced residual or metastatic lesions after nephrectomy was studied in regard to the survival rates. Although there was no complete or partial regression in tumor size, the survival rate of patients with 1 or more receptors was significantly higher than that of patients negative for receptors (p less than 0.01). In conclusion, hormonal manipulation in patients with renal cell carcinoma cannot induce an antitumor effect but seems to increase survival in patients with receptors.

Adenocarcinoma↗
PubMed1984

[Clinical evaluation of ceftizoxime in the treatment of complicated urinary tract infections].

Ceftizoxime (CZX) was given clinically to 80 patients with urogenital tract infections, in which 34 cases of complicated UTI satisfied the criteria of the UTI committee. CZX was administered for at least five days at a daily dose of 1 to 4 g in two divided doses by intravenous drip infusion. The overall clinical efficacy of CZX in 34 cases of complicated UTI was 59%, estimated by the criteria of the UTI committee. The overall clinical efficacy rate according to group of infection was: 64% for the 11 patients in the 1st group, 56% for the 9 patients in the 2nd group, 100% for the 5 patients in the 3rd group, 50% for the 4 patients in the 4th group and 20% for the 5 patients in the 5th group. No serious side effects were observed in the clinical or laboratory findings except for slight elevation in GOT & GPT values in two cases (2.5%), which returned to normal after CZX treatment. It is therefore suggested that CZX is a clinically useful and safe drug in the treatment of complicated UTI.

Adolescent↗
PubMed1984

[A case of vesical malacoplakia].

A 44-year-old woman was admitted to our hospital, complaining of terminal hematuria. On cystoscopy four yellow and soft nodular masses were observed in the bladder, one of which had central ulceration. TUR was performed for these masses. Histological examination revealed that they were vesical malacoplakia. The masses consisted of aggregates of macrophages with abundant cytoplasma in which typical Michaelis-Gutmann bodies were demonstrated by light and electron microscopies.

Adult↗
PubMed1984

[Chemotherapy after prostatectomy--effects of long term administration of Pivmecillinam (PMPC)].

The therapeutic efficacy of Pivmecillinam (PMPC) against urinary tract infections after prostatectomy was investigated. PMPC was orally administered at the dose of 300 mg/day for 2-14 weeks after initial intravenous postoperative chemotherapy with other antibiotics for 0-24 days (average 5.7 days). Thirty patients underwent retropubic prostatectomy and the other 59 patients received TUR-P. The chemotherapeutic efficacy for 19 patients who had over 10(3) CFU/ml of microorganisms was as follows: The effective rate was 48.4% after 2 weeks, 53.8% after 4 weeks, 66.7% after 5-6 weeks and 100% after 7-9 weeks. The prophylactic efficacy for 70 patients who had no or less than 10(3) CFU/ml of microorganisms was 64.3% after 2 weeks, 79.6% after 4 weeks, 86.7% after 5-6 weeks and 90.0% after 7-9 weeks. The overall clinical efficacy of PMPC for 89 patients was 60.7% after 2 weeks, 74.2% after 4 weeks, 83.3% after 5-6 weeks, 90.0% after 7-9 weeks and 100% after 10-14 weeks. No severe side effects were found in these 89 cases. In conclusion, PMPC is a useful drug for the long term treatment after prostatectomy.

Administration, Oral↗
PubMed1984

[Clinical management of testicular tumors].

Testicular tumor is a rare diseases in Japan. The incidence, histology, staging, tumor markers, treatment, and prognosis of this diseases are reviewed. Recently dramatic changes have occurred in the management of the disease, resulting in substantial improvement in ultimate survival. Many developments in chemotherapy, particularly the introduction of cis-platinum, have been largely responsible for this dramatic improvements in treatment and prognosis. Therapy depends a large extent upon the histological type and stage of the tumors, including tumor markers. Surgical excision of primary tumors followed by combination chemotherapy is primary mode of treatment in advanced testicular tumor cases. Standard chemotherapy for advanced tumors involves either cis-platinum, vinblastine, and bleomycin (PVB), or the above 3 drugs combined with actinomycin-D and cyclophosphamide (VAB-6). These regimens have produced complete remission rates of 50%-77% and improved the frequency of long-term survival. The treatment goal for this disease is cure. The achievement of disease free status, with aggressive combined chemotherapy and surgery or radiation is essential for reaching this goal.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1983

Combination chemotherapy including adriamycin for advanced transitional cell carcinoma of the urinary tract.

Thirty-three patients with advanced transitional cell carcinoma of the urinary tract (23 bladder cases, 8 ureter cases, and 2 renal pelvis cases) were treated by three-drug combination chemotherapy using two protocols (protocol I: Adriamycin 50 mg/m2, cyclophosphamide 500 mg/m2, and 5-fluorouracil 500 mg/m2, protocol II: Adriamycin 50 mg/m2, cyclophosphamide 500 mg/m2, and cis-platinum 50 mg/m2). Protocol I induced responses in three of 19 patients (16%), (1 complete response, 2 partial responses), and protocol II (I complete response, 4 partial responses) in five of 14 patients (36%). The overall response rate was 24%. The duration of response was relatively short (median duration 5.1 months). The combination therapy was relatively well tolerated except in three patients, including two mortalities. In our study, three-drug combination chemotherapy with Adriamycin, especially that including cis-platinum, was effective against transitional cell carcinoma of the urinary tract, but the results were not completely satisfactory.

Adult↗